Academic Salon Highlights of Molecular Diagnosis Advances in Thyroid Cancer

On January 12th, the "Academic Salon on Molecular Diagnosis Advances in Thyroid Cancer and the 55th Medical Perspective Cloud Classroom," hosted by Xiamen?Spacegen?Co.,Ltd., was successfully held in Shenzhen. Medical professors and experts gathered together to exchange academic insights, discuss the application value of precision detection in the diagnosis and treatment of thyroid disorders, and share clinical techniques and cutting-edge academic information.

This salon has the honor of inviting Professor Feng Duo from Huazhong University of Science and Technology Union Shenzhen Hospital and Professor Liu Hongguang from Shenzhen Second People's Hospital to serve as co-chairs of the conference. Professor Wang Youquan from Longhua District People's Hospital of Shenzhen and Professor Wu Xiaoqin from Huazhong University of Science and Technology Union Shenzhen Hospital will conduct special academic sessions, with numerous professors and experts participating in open discussions. The event promises to be a rich, expert-filled, and fascinating academic gathering.

?

Professor Feng Duo, in his speech, pointed out that in the current widespread promotion of the concept of "precision medicine," exploring how to achieve and optimize precise treatment strategies for thyroid cancer is an ongoing topic in the field. He hopes that this salon exchange can enhance clinical doctors' understanding of molecular diagnosis of thyroid cancer and promote clinical research in thyroid molecular diagnosis.

?

In his address, Professor Liu Hongguang expressed that in recent years, the incidence of thyroid cancer has continued to rise, and the mortality rate has also slightly increased. This has attracted attention in the academic community towards the standardization and treatment of thyroid cancer. He hopes that the conference will strengthen exchange and learning, collectively promoting the standardization and precision treatment of thyroid tumors.

Professor Wang Youquan gave a wonderful presentation on the "Clinical Value of Thyroid Cancer Gene Testing." He mentioned that currently, multiple guidelines and expert consensus emphasize that distinguishing between the benign and malignant nature of thyroid nodules is a key focus in clinical assessment and treatment. Preoperative identification of the nature of thyroid nodules can provide a basis for individualized and precise treatment of thyroid diseases. It is a crucial factor in the decision-making process for the diagnosis and treatment of thyroid diseases!

Professor Wu Xiaoqin conducted a case sharing session on thyroid cancer. In the sharing, Professor Wu Xiaoqin emphasized the significant role of genetic testing for thyroid cancer in preoperative diagnosis, guidance for surgical procedure selection, and clinical treatment guidance.

Professors Jin Ning from the Southern University of Science and Technology Hospital, Li Jie from the Shenzhen Qianhai Shekou Free Trade Zone Hospital, Prof. Xu Wentao from the Southern University of Science and Technology Hospital, Prof. Wei Wenjun from the Huazhong University of Science and Technology Union Shenzhen Hospital, Prof. Zhang Jun from the Shenzhen Qianhai Shekou Free Trade Zone Hospital, and Prof. Yu Tao from the Longhua People's Hospital of Shenzhen participated in the discussion session. The atmosphere during the on-site discussion was lively, with enthusiastic questions and the sharing of experiences and insights.

?

The meeting concluded with the summary of the chair professor. Through this salon learning format, the new achievements, progress, and trends in precision diagnosis and treatment of thyroid cancer were fully displayed and exchanged. It deepened everyone's understanding of thyroid diseases, opened up new ideas for diagnosis and treatment, enhanced clinical thinking abilities, and played a positive guiding and promoting role in improving the technical level of thyroid-related disease diagnosis and treatment.

?

Xiamen?Spacegen?Co.,Ltd.

Benefiting Public Health

Xiamen?Spacegen?Co.,Ltd.was established in 2015 and is a national high-tech enterprise settled in Xiamen's "Double Hundred Plan," led by entrepreneurial talents. The company relies on four core technology platforms, namely high-throughput sequencing (NGS), digital PCR, fluorescence quantitative PCR, and nucleic acid mass spectrometry. It is dedicated to providing comprehensive solutions for personalized and precise diagnosis of tumors, including early screening, disease diagnosis, personalized drug guidance, and efficacy monitoring. The company has two medical testing laboratories, Xiamen?SpaceSeq?MedLab?Co.,?Ltd. and Suzhou?SpaceSeq?MedLab?Co.,?Ltd., with a supporting 3500m2 GMP production workshop and a 2000m2 research and quality control laboratory. The quality management system has passed the TUV NORD ISO13485 certification. Spacegen has developed over 40 products, with three products obtaining National Medical Products Administration (NMPA) Class III medical device registration certificates, 10 products completing Class I medical device filing, and 22 products obtaining EU CE-IVD certification.